Re Cellceutix/ASCO: let us suppose that we are in fact at the presentation, right now:
Speaker:K has been so well-tolerated that we cannot yet find a maximum dosing. In fact, we are now 10 times our original dosing, and it may go higher.
Audience: (Hushed tones, or even whispers.)I told you that it was well-tolerated. Now do you believe me? Just show me a better tolerated anti cancer compound than that already.
Other audience members: tones not hushed, rise to their feet: Go higher, go higher with the doses! More cohorts! Higher and more!!
Speaker: Our next agenda is to work to find ideal doses and intervals. This may take some time.
Audience, murmurs: Time- we've got some more of that don't we? Surely we do. Safety first. It's Phase 1.
Other audience members, again the rabble, shouting, in a reprise: Higher and more! Higher and more!
Speaker: Also, as expected, p21 levels have risen in the later cohorts. If you will look at slide 17 you will see...
Audience, murmurs: Wasn't that in the corporate update? At least now we can get some details- look, actual data. I think that's a graph! Look!
Speaker: we plan to initiate the Bologna trials with Cytarabine and Kevetrin
Audience, chanting: Bologna, Bologna, Bologna
Speaker: There has been stabilization of tumors in some patients.
Audience, subdued: OK OK, here we are at the appropriate venue. This is it! This is what we came for. C'mon, c'mon...
Speaker: You must remember these are very small patient samples, and we hope to make more data available later.
Audience, crestfallen, building toward sullen: Is that all there is? Is that all there is? Special K?
Speaker: We expect more trial data to become available as new dosing regimens are in place.
Audience, stumbling toward exits: what room is the xyz presentation in? Do you think Brilacidin has anti-tumor activity? Wasn't this all in the update?
I hope I am wrong.
